Abstract
Liposomes are a prominent class of drug delivery nanoparticles. For currently approved liposomal therapeutics, drug is released predominantly via diffusion which has spatio‐temporal kinetic and bioavailability challenges, especially in a dynamic environment. Next‐generation liposome designs focus on stimuli‐triggered enhancement of drug release. One exciting approach here is liposomes that can be site‐specifically destabilized by disease‐associated enzymes. Feasibility of this has been demonstrated with certain phospholipases or metalloproteases, but a versatile strategy for designing liposomes triggerable by any disease‐specific enzyme remains lacking. We report a unique liposome design using enzyme‐cleavable stearyl‐peptide conjugates. Stearylamine has been explored for cationic liposomes in gene delivery, but the cationic charge poses significant cytotoxicity. We demonstrate that conjugating enzyme‐cleavable peptides to stearylamine and assembly of stearyl‐peptide conjugates within liposomes mitigates the cationic charge and significantly enhances biosafety. Surface‐decorating such liposomes with target‐specific ligands enables their active target‐anchorage under flow. Exposure of target‐anchored liposomes to disease‐relevant enzymes renders stearyl‐peptide cleavage and liposome destablization, enhancing drug release. We demonstrate the design versatility utilizing microfluidic models of three different vascular pathologies (hyperfibrinolysis, thrombosis and thromboinflammation) and delivering three corresponding drugs (tranexamic acid, tissue plasminogen activator and deoxyribonulease) triggered by three different enzymes (plasmin, thrombin and neutrophil elastase), respectively.

This publication has 83 references indexed in Scilit: